Issue #1 — Scams / Discernment / Marketing vs Medicine
Issue #2 — Hormone Balance Part I — The Ratio Framework
Prostate911 Newsletter
Thoughtful Notes for Clinicians and Patients Prostate Health, Research, and Long-Term Clarity
Issue #2
The Importance of Hormone Balance
Androgens, Estrogens, and the Prostate —
Why “More Testosterone” Is the Wrong Question
Clinical context: androgen–estrogen signaling balance in prostate biology.
Key idea: In an era of aggressive health marketing, distinguishing between clinical evidence and persuasive narrative has become an essential part of responsible medical decision-making.
If you spend time around prostate health discussions, you quickly encounter a familiar simplification: testosterone is either the villain or the solution. Both framings miss what clinicians already understand: biology rarely behaves like a single-dial system.
The prostate is hormone-responsive, but it is not governed by testosterone alone. It operates within a network of androgen signaling, estrogen signaling, receptor distribution, tissue metabolism, age-related endocrine shifts, and inflammatory context. The relevant question is not whether testosterone is “high” or “low,” but how the total signaling environment is being interpreted inside prostate tissue over time.
This is where hormone balance becomes more useful than hormone level.
Hormone balance refers to the relationship between androgens and estrogens rather than the isolated value of either hormone alone. Several lines of research suggest that relative signaling between these pathways may influence prostate biology more meaningfully than absolute testosterone concentration.
In one human analysis, Black and colleagues examined circulating sex steroid metabolites in relation to aggressive prostate cancer risk (https://pubmed.ncbi.nlm.nih.gov/25178985/). Rather than asking whether testosterone alone predicted risk, they examined the estradiol-to-testosterone ratio. Men in the highest ratio category had a substantially lower risk of aggressive prostate cancer compared with men in the lowest category. Individual hormone levels, when examined alone, were not strongly predictive. The relationship appeared only when the hormones were interpreted relative to each other.
This does not establish an “ideal” ratio. It does not suggest that increasing estrogen is protective. It suggests that endocrine context may matter more than a single laboratory number.
Other cohort analyses have not demonstrated a uniform relationship between the estradiol:testosterone ratio and overall prostate cancer incidence or grade (https://www.sciencedirect.com/science/article/abs/pii/S0090429508015628/). Assay methods differ. Timing of blood collection differs. Prostate cancer itself represents multiple biologically distinct subtypes. Epidemiology reflects probabilities, not certainties.
The ratio concept becomes more compelling at the tissue level. Aromatase — the enzyme that converts testosterone into estradiol — is active within prostate stromal tissue. Local estrogen production can shift the androgen-to-estrogen environment within the gland even when circulating serum values appear stable (https://www.sciencedirect.com/science/article/abs/pii/S0960076009002696/).
Experimental models reinforce this principle. In benign prostatic hyperplasia models, administration of testosterone combined with estradiol produces enlargement patterns not seen when either hormone acts alone (https://pmc.ncbi.nlm.nih.gov/articles/PMC3473198/). Growth behavior changes when the balance changes.
Taken together, human cohort data, tissue-level research, and experimental models converge on a consistent theme: endocrine signaling in the prostate is relational. The balance between androgen and estrogen activity — modified by age, metabolism, inflammation, and genetics — may carry more biological meaning than either hormone level considered in isolation.
Epidemiology and Restraint
Online narratives often claim that “estrogen causes prostate cancer” or that testosterone therapy inevitably fuels malignancy. Large epidemiologic analyses do not support such simplistic conclusions.
A prospective analysis in Cancer Epidemiology, Biomarkers & Prevention found no simple linear relationship between circulating estradiol and overall prostate cancer risk (https://pubmed.ncbi.nlm.nih.gov/16434592/). A broader review emphasized variability and study limitations (https://pmc.ncbi.nlm.nih.gov/articles/PMC3139891/).
More recently, researchers at Oxford’s Cancer Epidemiology Unit reported associations between circulating testosterone, IGF signaling, and aggressive prostate cancer risk in large datasets (https://www.ceu.ox.ac.uk/news/largest-study-to-date-confirms-role-of-two-hormones-in-aggressive-prostate-cancer-risk/). Even here, interpretation requires nuance. Association does not equal destiny. Hormones operate within metabolic, genetic, and inflammatory frameworks.
The consistent pattern is this: hormone signaling influences prostate biology, but rarely in a way that fits slogans.
Clinical Framing
For clinicians, endocrine discussions increasingly involve helping patients interpret internet narratives that reduce complex physiology to optimization formulas.
For patients, the key principle is proportion. Prostate tissue responds to a signaling environment — not to marketing language.
Hormone balance is not a product category. It is a reminder that endocrine signals are interpreted locally, modulated enzymatically, and influenced by age and metabolic context. The prostate listens to more than one messenger at once.
Complex organs deserve proportionate thinking.
Hormone balance, however, is only part of the picture. Hormones are not static molecules; they are actively converted within prostate tissue through specific enzymatic pathways. Those conversion processes can shift local signaling even when blood levels appear unchanged. In the next issue, we will look more closely at how those pathways operate — and why modifying them can measurably alter prostate behavior over time.
Warmly,
Jean-Claude
Why this newsletter exists
You’re receiving this because you chose to be here, and I don’t take that lightly.
When I was first navigating prostate cancer and BPH, what struck me most was not simply the medical complexity, but the emotional atmosphere surrounding it. Information was scattered across websites, forums, and advertisements. Some of it was useful. Much of it was contradictory. A great deal of it felt urgent, persuasive, or subtly manipulative. What I longed for was something steadier — a place where ideas could be examined carefully, without pressure, without alarm, and without an agenda quietly steering the conversation.
That is the spirit in which this newsletter is written.
My intention is to read widely, think slowly, and share what appears thoughtful and relevant, while acknowledging uncertainty where it exists. The goal is not to overwhelm you with data, nor to convince you of anything in particular, but to create a quieter space where informed decisions can take shape at their own pace. In matters of health, clarity and patience tend to serve us far better than urgency and reaction.
If these notes help you feel more oriented, more grounded, or simply less alone in the process, then they are doing what they were meant to do.
Explore the Newsletter Archive
If you would like to explore additional topics, you can visit the full archive here:
https://Prostate911.info/newsletter-archive
There is no required order and no expectation to read everything. Simply begin where your curiosity leads and move at whatever pace feels natural.
If this has been helpful
If someone in your life is quietly navigating BPH or prostate cancer and might benefit from information that is calm, organized, and free of pressure, you are welcome to share the free book with them:
There is no registration and no email requirement. It is simply there for anyone who needs it, presented in one place so others do not have to sift through the same confusion many of us faced.
If you are interested in the specific circulation and detoxification approach that I personally explored — the one that helped reduce my nocturia and improve my own markers — you are welcome to email me directly at:
I am always glad to share what I did and what I learned, not as a prescription, but as part of an ongoing conversation among thoughtful adults trying to make sense of complex terrain....
If you feel that this work has been meaningful to you, and you would like to support it, there is one more way to do that.
The path I’ve walked with prostate cancer and BPH has not been short, and it has not been free of anxiety. There were long stretches of uncertainty, late nights reading medical papers, difficult conversations, second opinions, and the quiet weight that sits in the background when your health feels uncertain. Over time, I realized that much of what I eventually learned was scattered and difficult to access, and that many men were walking the same path alone.
For that reason, I made a deliberate choice to gather what I could, organize it carefully, and make it freely available. The book is available without registration. The website does not sit behind a paywall. The newsletter is open to anyone who finds it helpful. Hosting costs, research time, editing, and design have all been covered personally because I wanted the information to remain accessible to anyone who might need it, regardless of their circumstances.
If you feel moved to support that effort — not as a purchase, but as a gesture of appreciation for the time and care that go into it — you are welcome to buy me a cup of coffee here:
https://buymeacoffee.com/jckoven
Preferences
If these notes ever stop being helpful, you can unsubscribe at any time: {$unsubscribe}